[Current treatment strategies for multiple myeloma]
1Department Innere Medizin, Medizinische Onkologie, Kantonsspital Graubünden, Chur. ulrich.mey@ksgr.ch
Therapeutische Umschau. Revue Therapeutique
|October 2, 2010
Summary
Novel agents like thalidomide, bortezomib, and lenalidomide have transformed multiple myeloma treatment, improving patient outcomes. This review details their integration for newly diagnosed and relapsed patients, both transplant-eligible and ineligible.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Multiple myeloma treatment has evolved significantly.
- Novel agents have expanded therapeutic options and improved prognosis.
- Key novel agents include thalidomide, bortezomib, and lenalidomide.
Purpose of the Study:
- To summarize clinical trial results on novel agents in multiple myeloma.
- To focus on integrating these agents in various treatment settings.
- To provide recommendations for novel agent use based on current data.
Main Methods:
- Review of large clinical trial data.
- Focus on newly diagnosed and relapsed/refractory multiple myeloma.
- Consideration of transplant-eligible and non-eligible patient groups.
Main Results:
- Novel agents have substantially improved multiple myeloma prognosis.
- Effective integration strategies exist for different patient populations.
- Treatment recommendations are based on robust clinical evidence.
Conclusions:
- Novel agents represent a major advancement in multiple myeloma therapy.
- Personalized treatment approaches incorporating novel agents are crucial.
- Continued research will further refine optimal therapeutic strategies.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...